| |
|
|
|
Westin Boston Waterfront, Boston, MA, USA
May 21-22, 2014
Experimental methods such as X-ray crystallography, NMR, and computational chemistry techniques have led to a better understanding and larger knowledge base of 3-dimensional structures and binding events, encouraging rapid development of structure-based drug design. Cambridge Healthtech Institute’s Fourteenth Annual Structure-Based Drug Design event will showcase informative, high-quality case studies, innovative techniques, and strategies to move from computation to experiment, and finally, to drug. Top scientists from pharma and biotech will address how they are hitting epigenetic targets, provide updates on the newest wave of GPCRs and other membrane proteins, and discuss the latest in fragment-based drug design. Attendees will return to their organizations with fresh perspectives and new ideas to maximize productivity and increase successes in drug discovery.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- Chas Bountra, Ph.D., Professor, Translational Medicine, Department of Clinical Medicine; Associate Head, Medical Sciences; Chief Scientist, Structural Genomics Consortium, University of Oxford
- Nicolas Foloppe, Ph.D., Principal Scientist, Chemistry, Vernalis R&D Ltd.
- Yong Tang, Ph.D., Scientist, Structural Biology Department, Constellation Pharmaceuticals
- Andrew W. Stamford, Ph.D., Executive Director, Discovery Chemistry, Merck Research Laboratories
- Dafydd Owen, Ph.D., Associate Research Fellow, Biotherapeutics Worldwide R&D, Pfizer Worldwide Medicinal Chemistry
- Gregory L Warren, Ph.D., Senior Applications Scientist, OpenEye Scientific Software, Inc
- Marcel Verdonk, Director, Computational Chemistry & Informatics, Astex
- Daniel A. Erlanson, Ph.D., President, Carmot Therapeutics, Inc.
- Jonathan S. Mason, Ph.D., FRSC, Senior Research Fellow, Heptares Therapeutics UK
- Kerim Babaoglu, Ph.D., Associate Principal Scientist, Computational Chemistry, Merck
- Carleton Sage, Ph.D., Fellow, Computational Systems, Arena Pharmaceuticals
- Karen A. Rossi, MS, Senior Research Investigator, Computer-Assisted Drug Design, Bristol-Myers Squibb Company
- Woody Sherman, Ph.D., Vice President, Applications Science, Schrödinger, Inc.
- Jose Duca, Ph.D., Head, Computer-Aided Drug Discovery, Novartis
- Carlos J. Camacho, Ph.D., Associate Professor, Computational Biology, University of Pittsburgh; Co-Founder & Co-Chairman, Scientific Advisory Board, Carmolex
- Anders Hogner, Ph.D., Associate Director, Computational Chemistry, CVMD Innovative Medicines, AstraZeneca
- Jason Burch, Ph.D., Scientist, Medicinal Chemistry, Genentech
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|